<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381325</url>
  </required_header>
  <id_info>
    <org_study_id>MSB0254-CSP-001</org_study_id>
    <nct_id>NCT04381325</nct_id>
  </id_info>
  <brief_title>A Study of MSB0254 Injection in Advanced Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabspace Biosciences (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabspace Biosciences (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was an open, multi-dose dose escalation phase I clinical study to evaluate the
      safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or
      metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MSB0254</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Measured by number adverse events that are related to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD) or recommended phase2 dose（RP2D）</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Measured by number of subjects experiencing DLT in each escalation cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for MSB0254</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Changes in AUC over time in subjects with MSB0254</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration (Cmax)for MSB0254</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Tmax is the time in hours/days to reach Cmax following dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>The time required for the plasma level of the study drug to decrease by one-half during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunogenicity of MSB0254 injection</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>The immunogenicity of MSB0254 injection was evaluated by testing the production of anti-drug antibody (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MSB0254 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0254 Injection</intervention_name>
    <description>An intravenous infusion with concentration from 4 mg/kg to 20 mg/kg every 2 weeks (Q2W).</description>
    <arm_group_label>MSB0254 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary informed consent, knowledge of the study and willingness to follow and has
             ability to complete all trial procedures

          -  There is a histologically or cytologically confirmed, locally advanced or metastatic
             tumor by standard treatment failure or lack of standard treatment or inability to
             tolerate standard treatment;

          -  The eastern United States cooperative tumor group (ECOG) score was 0 or 1

          -  Expect to survive at least 3 months

          -  Must have at least one assessable lesion as defined in RECIST v1.1;

          -  Suitable organs and hematopoietic function should be available. Laboratory tests
             during screening should meet the appropriate criteria:

          -  Male and female subjects of childbearing age will agree to use effective,
             investigator-approved contraceptive methods from the date of the informed consent
             until 3 months after the last administration

        Exclusion Criteria:

          -  Patients with symptoms of brain or pia meningeal metastases.

          -  The lung metastasis of the tumor has a cavity, or the investigator judges that there
             is bleeding tendency or bleeding risk;

          -  patients requiring local treatment or repeated drainage, the investigator identified
             poorly controlled effusion of the body cavity (pleural fluid, ascites, pericardial
             effusion, etc.)

          -  The adverse reactions of previous treatment did not recover to CTCAEv5.0 score ≤1
             (excluding hair loss and anemia);

          -  Had received any previous systemic therapy targeting VEGF or VEGFR2 signaling pathway;

          -  Drugs or chemotherapy or radiotherapy received in other clinical trials within 4 weeks
             prior to enrollment (mitomycin C and nitrosorea should be administered at least 6
             weeks before the last dose)

          -  Patients who had major surgery within 4 weeks prior to screening (excluding needle
             biopsy) and who were expected to have major surgery during the study period (including
             the 28-day screening period) or had severe unhealed wounds, ulcers, or trauma

          -  Left ventricular ejection fraction ≤50%;

          -  Heart failure patients with greater than or equal to Ⅱ level（NYHA）;

          -  Clinically significant arrhythmias (including frequent ventricular premature beats,
             symptomatic or treatable ventricular tachycardia, and asymptomatic persistent
             ventricular tachycardia);

          -  Uncontrolled hypertension or hypertension that requires two or more medications to
             control within the normal range (systolic &gt; 150mmHg and/or diastolic &gt; 90mmHg);

          -  There are currently venous thromboemboli that require treatment;

          -  Myocardial infarction, stroke or other severe arterial thromboembolism events occurred
             within 6 months before enrollment.

          -  Any grade 2 or more bleeding occurred within 6 months prior to enrollment;

          -  Intraperitoneal abscess, or abdominal wall fistula, gastrointestinal perforation, or a
             history of poorly controlled/recurrent inflammatory bowel disease (including crohn's
             disease or ulcerative colitis) occurred within 6 months prior to enrollment.

          -  The patient is receiving （NSAIDS;Such as indomethacin, ibuprofen, naproxen or similar
             drugs) or antiplatelet drugs (such as clopidogrel, ticlopidine, dipyridamole or
             analgrel) for long-term treatment;Aspirin is permitted with a maximum dose of 325 mg
             per day;Celecoxib is permitted for analgesic treatment;However, low-dose aspirin
             (≤325mg/d) and celecoxib should not be used at the same time.

          -  Patients are known to be allergic to MSB0254 or its excients, monoclonal antibodies,
             or any other therapeutic protein, such as fresh frozen plasma, human serum albumin
             (HSA), cytokines, or interleukin.If severe allergic reactions are suspected (CTCAE
             v5.0 grade ≥3), the patient should be excluded.

          -  Urine protein concentration of patients according to dipstick or routine urine
             analysis (UA) is ＞1 +,The patients also had edema or serum albumin levels below the
             lower limit of the normal range (LLN).Alternatively, if the urine protein
             concentration of the patient is ≥2+ according to the dipstick or routine urine
             analysis, the urine protein concentration in the 24-hour urine protein analysis must
             be＞1g, accompanied by edema or serum albumin lower than LLN;

          -  Patients with a known history of hepatitis c or chronic active hepatitis b. Except for
             HBV carriers, hepatitis b patients who are stable after drug treatment (hbv-dna titer
             must not be higher than 1000 copies [CPS]/mL or 200 IU/mL) and hepatitis c patients
             who are stable after drug treatment (hcv-rna negative)

          -  A known history of HIV infection or a positive test for human immunodeficiency virus
             (HIV);

          -  Positive treponema pallidum test;

          -  A history of alcohol, drug or substance abuse in the past 1 year;

          -  Has a clear history of neurological or mental disorders, such as epilepsy or dementia;

          -  Poor compliance of the subject;

          -  Women who are pregnant (confirmed by a urine or serum pregnancy test) or
             breast-feeding;

          -  the investigators concluded that the study was not suitable for participants for other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mengde Wang</last_name>
    <role>Study Director</role>
    <affiliation>Mabspace Biosciences (Suzhou) Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Yue</last_name>
    <phone>+86-512-67079200</phone>
    <phone_ext>8009</phone_ext>
    <email>ming.yue@transcenta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Sun</last_name>
    <phone>+86-512-67079200</phone>
    <phone_ext>8009</phone_ext>
    <email>ling.sun@transcenta.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FuDan University ZhongShan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TianShu Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

